COVI-VAC (U.S. COVID-19 vaccine)

This article is about COVID-19 vaccine developed by Codagenix, Inc.. For other uses, see Covivac (disambiguation).

COVI-VAC (U.S. COVID-19 vaccine)

Vaccine description
Target	SARS-CoV-2
Vaccine type	Attenuated
Clinical data
Trade names	CDX-005
Other names	Covi-Vax
Routes of administration	Intranasal
Identifiers
CAS Number	2695472-84-3

COVI-VAC (codenamed CDX-005) is a COVID-19 vaccine developed by Codagenix, Inc. In December 2020, COVI-VAC started a Phase I clinical trial, involving 48 participants. The trial was scheduled to complete in June 2021, with results to be reported by May 2022. On September 29, 2021, Codagenix presented positive phase 1 data for COVI-VAC at IDWEEK2021. Data indicates that COVI-VAC is well tolerated, with no significant adverse events reported and that administration of the intranasal vaccine was immunogenic and capable of blocking nasal replication of the virus with minimal viral shedding, recorded at levels lower than those likely to result in subsequent transmission of COVID-19. Furthermore, COVI-VAC was shown to stimulate both serum and mucosal antibody immune responses.

Medical uses

The vaccine is administered intranasally and requires a single dose.

Pharmacology

COVI-VAC is a live attenuated vaccine.

Clinical trials

Phase I

In December 2020, Codagenix started a Phase I trial in the United Kingdom.

In September 2021, Codagenix reported that the trial had shown COVI-VAC to be safe and immunogenic.

Further reading

• Codagenix, Inc (26 July 2021). "First-in-human, Randomised, Double-blind, Placebo-controlled, Dose-escalation Study in Healthy Young Adults Evaluating the Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Candidate for Prevention of COVID-19".